Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2008
|
| gptkbp:ATCCode |
J05AG04
|
| gptkbp:bioavailability |
unknown
|
| gptkbp:brand |
gptkb:etravirine
|
| gptkbp:CASNumber |
269055-15-4
|
| gptkbp:chemicalFormula |
C20H15BrClN6O
|
| gptkbp:contraindication |
hypersensitivity to etravirine
|
| gptkbp:drugClass |
non-nucleoside reverse transcriptase inhibitor
|
| gptkbp:eliminationHalfLife |
41 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Intelence
|
| gptkbp:indication |
treatment-experienced HIV-1 patients
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:metabolism |
liver (CYP3A, CYP2C9, CYP2C19)
|
| gptkbp:pregnancyCategory |
B
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea rash |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:etravirine
|
| gptkbp:bfsLayer |
6
|